Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.